Boehringer: By that time we will be well established in diabetes treatment
Boehringer Ingelheim is getting seriously ready to take on Novo Nordisk in the European diabetes market, according the company’s head of marketing. Even though Boehringer is relatively new within the diabetes field, according to the executive, it boasts significant experience from other chronic illnesses and an alliance which it can draw on. Nor is the company wringing its hands over new, strong data from Novo.
BY STEFAN SINGH KAILAY
INGELHEIM
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo’s prize asset shows potential in Alzheimer’s
For abonnenter
Boehringer appoints new chief of Danish unit
For abonnenter
